Lokken Investment Group LLC Trims Stake in Johnson & Johnson $JNJ

Lokken Investment Group LLC lowered its stake in Johnson & Johnson (NYSE:JNJ) by 0.9% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,854 shares of the company’s stock after selling 82 shares during the quarter. Lokken Investment Group LLC’s holdings in Johnson & Johnson were worth $1,353,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Highline Wealth Partners LLC raised its holdings in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new position in Johnson & Johnson in the 1st quarter valued at $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the 1st quarter valued at $48,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson in the 1st quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson in the 1st quarter valued at $52,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.2%

Shares of NYSE JNJ opened at $190.66 on Friday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $192.10. The company has a market cap of $459.16 billion, a P/E ratio of 20.39, a P/E/G ratio of 2.40 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a fifty day moving average price of $178.48 and a 200 day moving average price of $163.76.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $24.02 billion during the quarter. Research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Analysts Set New Price Targets

JNJ has been the subject of several analyst reports. Bank of America boosted their price target on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Weiss Ratings upgraded Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. Royal Bank Of Canada restated an “outperform” rating and set a $209.00 price objective on shares of Johnson & Johnson in a report on Friday. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Finally, UBS Group set a $198.00 price objective on Johnson & Johnson in a report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $192.94.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.